Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.
| Revenue (TTM) | $63.30M |
| Gross Profit (TTM) | $48.50M |
| EBITDA | $-38.26M |
| Operating Margin | -58.30% |
| Return on Equity | -66.10% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $2.48 |
| Book Value | $3.09 |
| Price-to-Book | 4.64 |
| Price-to-Sales (TTM) | 5.94 |
| EV/Revenue | 5.11 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 56.70% |
| Shares Outstanding | $27.30M |
| Float | $15.67M |
| % Insiders | 44.42% |
| % Institutions | 40.30% |
Volatility is currently contracting
Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event.
Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar spine fusion procedures Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar spine fusion procedures
Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions today announced that management will participate in the following investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference.
CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the first quarter ended March 31, 2026.
CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CARL and any ticker you trade — then tracks every position and per-strategy win rate.
